[go: up one dir, main page]

NO20050956L - Fremgangsmate og doseringsformer for kontrollert levering av paliperidon - Google Patents

Fremgangsmate og doseringsformer for kontrollert levering av paliperidon

Info

Publication number
NO20050956L
NO20050956L NO20050956A NO20050956A NO20050956L NO 20050956 L NO20050956 L NO 20050956L NO 20050956 A NO20050956 A NO 20050956A NO 20050956 A NO20050956 A NO 20050956A NO 20050956 L NO20050956 L NO 20050956L
Authority
NO
Norway
Prior art keywords
paliperidone
dosage forms
controlled delivery
delivery
controlled
Prior art date
Application number
NO20050956A
Other languages
English (en)
Other versions
NO324821B1 (no
Inventor
Atul Devdatt Ayer
Noymi Yam
Iran Reyes
Nipun Davar
Julie Lee
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31191280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20050956(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20050956L publication Critical patent/NO20050956L/no
Publication of NO324821B1 publication Critical patent/NO324821B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20050956A 2002-07-29 2005-02-22 Doseringsform omfattende paliperidon eller risperidon med en vesentlig okende frigivningshastighet samt anvendelse av paliperidon eller risperidon NO324821B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39959002P 2002-07-29 2002-07-29
US40600502P 2002-08-26 2002-08-26
PCT/US2003/023433 WO2004010981A1 (en) 2002-07-29 2003-07-28 Methods and dosage forms for controlled delivery of paliperidone

Publications (2)

Publication Number Publication Date
NO20050956L true NO20050956L (no) 2005-04-27
NO324821B1 NO324821B1 (no) 2007-12-10

Family

ID=31191280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050956A NO324821B1 (no) 2002-07-29 2005-02-22 Doseringsform omfattende paliperidon eller risperidon med en vesentlig okende frigivningshastighet samt anvendelse av paliperidon eller risperidon

Country Status (28)

Country Link
US (1) US20040092534A1 (no)
EP (1) EP1539115B1 (no)
JP (1) JP4500679B2 (no)
KR (1) KR100699516B1 (no)
CN (1) CN1684670A (no)
AR (1) AR040721A1 (no)
AT (1) ATE373472T1 (no)
AU (1) AU2003256844A1 (no)
BR (1) BR0313139A (no)
CA (1) CA2494234C (no)
CO (1) CO5580742A2 (no)
CY (1) CY1107096T1 (no)
DE (1) DE60316454T2 (no)
DK (1) DK1539115T3 (no)
ES (1) ES2293039T3 (no)
HR (1) HRP20050077B1 (no)
IL (1) IL166489A (no)
MX (1) MXPA05001191A (no)
MY (1) MY137049A (no)
NO (1) NO324821B1 (no)
NZ (1) NZ570198A (no)
PE (1) PE20040132A1 (no)
PL (1) PL210119B1 (no)
PT (1) PT1539115E (no)
RU (1) RU2321391C2 (no)
TW (1) TWI363637B (no)
WO (1) WO2004010981A1 (no)
ZA (1) ZA200501641B (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
CA2575484A1 (en) * 2004-08-04 2006-02-16 Alza Corporation Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition
US20060189635A1 (en) * 2005-02-04 2006-08-24 Michelle Kramer Enhanced efficacy benzisoxazole derivative dosage forms and methods
WO2006085856A1 (en) * 2005-02-04 2006-08-17 Alza Corporation Methods and dosage forms for reducing side effects of benzisozazole derivatives
WO2007019393A2 (en) * 2005-08-04 2007-02-15 Alza Corporation Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
WO2007081736A1 (en) * 2006-01-06 2007-07-19 Alza Corporation Osmotic dosage form with controlled release and fast release aspects
SI1993559T1 (sl) 2006-02-03 2017-01-31 Opko Renal, Llc Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3
US20070232624A1 (en) * 2006-04-03 2007-10-04 Palumbo Joseph M Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
DK3357496T3 (da) 2006-06-21 2020-05-11 Opko Ireland Global Holdings Ltd Terapi ved brug af vitamin d-repletteringsmiddel og vitamin d-hormonsubstitutionsmiddel
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
PT2148684E (pt) 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
ES3047207T3 (en) * 2007-04-25 2025-12-03 Opko Renal Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
PT2148661E (pt) 2007-04-25 2013-03-06 Proventiv Therapeutics Llc Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso
ES2374200T3 (es) * 2007-08-21 2012-02-14 Teva Pharmaceutical Industries Ltd. Formulación de liberación prolongada de paliperidona.
EP2081556A1 (en) 2007-09-25 2009-07-29 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
HUE053904T2 (hu) * 2007-12-19 2021-07-28 Janssen Pharmaceutica Nv Hosszan tartó hatású injektálható paliperidon-észterekkel kapcsolatos adagolási rendek
WO2009118655A2 (en) * 2008-03-27 2009-10-01 Actavis Group Ptc Ehf Highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity
WO2010009900A1 (en) * 2008-07-25 2010-01-28 Krka, D.D. Novo Mesto Paliperidone composition comprising solid matrix particles
EP2161019A1 (en) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
WO2010044097A2 (en) 2008-09-15 2010-04-22 Intas Pharmaceuticals Limited Novel dosage form of paliperidone and process for preparing the same
RU2510266C2 (ru) * 2008-09-30 2014-03-27 Эндо Фармасьютикалз Солюшнз Инк. Имплантируемое устройство для доставки рисперидона и способы его применения
WO2011018246A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Controlled release paliperidone composition
US20110052687A1 (en) * 2009-08-26 2011-03-03 Glenmark Generics Ltd Extended release pharmaceutical composition of paliperidone
AU2010308021A1 (en) * 2009-10-16 2012-05-17 Ranbaxy Laboratories Limited Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
EP2547206B1 (en) * 2010-03-15 2016-05-11 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
MX339805B (es) * 2010-04-22 2016-06-10 Intra Cellular Therapies Inc Compuestos organicos.
WO2012014052A2 (en) 2010-07-30 2012-02-02 Micro Labs Limited Novel coated extended release pharmaceutical compositions containing paliperidone
CN102058517A (zh) * 2010-12-31 2011-05-18 泰州万全医药科技有限公司 一种帕潘立酮缓释剂及其制备方法
US20130034605A1 (en) 2011-08-01 2013-02-07 Micro Labs Limited Extended release pharmaceutical compositions containing paliperidone
CN102274164B (zh) * 2011-08-22 2014-07-02 长春健欣生物医药科技开发有限公司 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂
MX2014012374A (es) 2012-04-14 2015-04-17 Intra Cellular Therapies Inc Compuestos organicos.
WO2014102741A2 (en) * 2012-12-28 2014-07-03 University Of The Witwatersrand, Johannesburg Pharmaceutical dosage form
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CN103271889B (zh) * 2013-05-23 2015-10-28 沈阳药科大学 帕利哌酮新型递增释放渗透泵制剂及其制备方法
CN103385857A (zh) * 2013-06-29 2013-11-13 北京万全德众医药生物技术有限公司 帕利哌酮的药物组合物
WO2015001488A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Extended-release tablets of paliperidone and processes of preparation thereof
EP3076967B1 (en) 2013-12-03 2021-07-28 Intra-Cellular Therapies, Inc. Methods for treating residual symptoms of schizophrenia
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US20160000654A1 (en) * 2014-07-07 2016-01-07 Cadila Healthcare Limited Method for determining formulation orientation of asymmetric multi-layered osmotic tablets
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104257622B (zh) * 2014-10-01 2020-02-07 浙江华海药业股份有限公司 一种帕利哌酮控释片及其制备方法
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
GR1008842B (el) 2015-08-06 2016-09-05 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου
CN105147629B (zh) * 2015-09-24 2017-08-25 吉林大学 一种异丁利酮片剂及制备方法
RU2743513C2 (ru) 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
JP6686168B2 (ja) 2016-03-25 2020-04-22 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
WO2017182237A1 (en) 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment
WO2017174096A1 (en) 2016-04-05 2017-10-12 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018098115A1 (en) * 2016-11-23 2018-05-31 Children's Hospital Medical Center Paliperidone for treatment of drug refractory irritability and autism spectrum disorder
CN106727392A (zh) * 2016-12-15 2017-05-31 上海奕利制药有限公司 一种帕利哌酮缓释片剂及其制备方法
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
MX387784B (es) 2017-03-24 2025-03-18 Intra Celular Therapies Inc Composiciones novedosas y metodos.
IL272249B2 (en) 2017-07-26 2023-11-01 Intra Cellular Therapies Inc Organic compounds
CA3071137A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Prodrugs of substituted heterocycle fused gamma-carbolines
IL277509B2 (en) 2018-03-23 2023-11-01 Intra Cellular Therapies Inc Organic compounds
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
CA3102948A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
CA3108558A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
EP3843738A4 (en) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. NEW METHODS
CN114072150A (zh) 2019-07-07 2022-02-18 细胞内治疗公司 新方法
KR102285510B1 (ko) 2019-10-29 2021-08-04 강동국 양액 농도조절용 캡슐 및 그 용도
JP2024515220A (ja) 2021-04-26 2024-04-05 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
CN113616610B (zh) * 2021-07-30 2023-05-12 石药集团欧意药业有限公司 一种帕利哌酮缓释片及其制备方法
US20230364009A1 (en) * 2022-05-12 2023-11-16 Celanese Eva Performance Polymers Llc Implantable Medical Device for the Delivery of an Antipsychotic
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
AU2023418793A1 (en) 2022-12-30 2025-06-12 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656092A (en) * 1985-10-15 1987-04-07 R. P. Scherer Corporation Target shooting capsules
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
ES2308955T5 (es) * 1993-09-28 2012-04-03 R.P. Scherer Gmbh Fabricación de cápsulas de gelatina blanda
AU694147B2 (en) * 1993-11-19 1998-07-16 Alkermes, Inc. Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
WO1998006380A2 (en) * 1996-08-16 1998-02-19 Alza Corporation Dosage form for providing ascending dose of drug
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DE69920689T2 (de) * 1998-06-03 2005-02-24 Alza Corp., Mountain View Vorrichtungen zum Aufrechterhalten eines gewünschten therapeutischen Medikamenteneffekts über einen verlängerten Therapiezeitraum
US6706282B1 (en) * 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
WO2000025790A1 (en) * 1998-11-02 2000-05-11 Alza Corporation Controlled delivery of antidepressants
AU765909C (en) * 1998-12-17 2004-09-23 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
EP1169024B1 (en) * 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6375981B1 (en) * 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
US6530962B1 (en) * 2001-08-31 2003-03-11 R.P. Scherer Technologies, Inc. Emulsion of water soluble dyes in a lipophilic carrier

Also Published As

Publication number Publication date
ATE373472T1 (de) 2007-10-15
AR040721A1 (es) 2005-04-20
JP4500679B2 (ja) 2010-07-14
NZ570198A (en) 2010-01-29
EP1539115B1 (en) 2007-09-19
CN1684670A (zh) 2005-10-19
HK1072559A1 (en) 2005-09-02
CY1107096T1 (el) 2012-10-24
WO2004010981A1 (en) 2004-02-05
ES2293039T3 (es) 2008-03-16
KR20050044895A (ko) 2005-05-13
CO5580742A2 (es) 2005-11-30
TWI363637B (en) 2012-05-11
EP1539115A1 (en) 2005-06-15
CA2494234A1 (en) 2004-02-05
RU2005102105A (ru) 2005-08-10
DE60316454T2 (de) 2008-06-26
PL210119B1 (pl) 2011-12-30
BR0313139A (pt) 2005-07-05
DK1539115T3 (da) 2008-01-28
IL166489A0 (en) 2006-01-15
HRP20050077B1 (hr) 2013-11-22
AU2003256844A1 (en) 2004-02-16
PE20040132A1 (es) 2004-03-06
MY137049A (en) 2008-12-31
KR100699516B1 (ko) 2007-03-26
TW200418524A (en) 2004-10-01
US20040092534A1 (en) 2004-05-13
PT1539115E (pt) 2008-01-14
DE60316454D1 (de) 2007-10-31
JP2005535682A (ja) 2005-11-24
RU2321391C2 (ru) 2008-04-10
NO324821B1 (no) 2007-12-10
HRP20050077A2 (en) 2005-12-31
CA2494234C (en) 2009-10-27
MXPA05001191A (es) 2005-09-12
ZA200501641B (en) 2005-08-31
PL376258A1 (en) 2005-12-27
IL166489A (en) 2014-01-30

Similar Documents

Publication Publication Date Title
NO20050956L (no) Fremgangsmate og doseringsformer for kontrollert levering av paliperidon
NO20042993L (no) Formulering og doseringsform for kontrollert levering av terapeutiske midler
PL367272A1 (en) Novel substituted benzimidazole dosage forms and method of using same
NO20031581D0 (no) Fremgangsmåte og system for autentisering av komponenter i et grafikksystem
DK1298282T3 (da) Fremgangsmåde og indretning til syrebehandling af en underjordisk formation i borehuller
FI20012017A0 (fi) Menetelmä ja laite magneettistimulaation annoslaskentaa varten
DK1415535T3 (da) Spröjtesystem og fremgangsmåde til et sådant
EP1478345A4 (en) NOVEL PHARMACEUTICAL DOSAGE FORMS AND PROCESS FOR PRODUCTION OF SAID DOSAGE FORMS
AU2003265618A8 (en) Method and apparatus of position location
SG116507A1 (en) Pharmaceutical dosage form and method of making.
NO20030438D0 (no) Fremgangsmåte og anordning for stöping av betongprodukter
NO20053874L (no) Formulering og metoder for behandling av thrombocytemi
NO20044342L (no) Androgent farmasoytisk preparat og fremgangsmate for behandling av depresjon
NO20041076L (no) Anlegg og fremgangsmate for stoping, saerlig av elektroder
IS7542A (is) Kerfi og aðferð við að mynda hleðslueiningar
SG103888A1 (en) Method and apparatus for the control of building functional units
GB0203518D0 (en) Wager administration system and method of operation thereof
NO20033155D0 (no) Fremgangsmate for hormonerstatningsterapi og dens administreringsform
IL162716A0 (en) Oral pharmaceutical compositions for soft capsulescontaining vinorelbine and method of treatment
GB0208897D0 (en) New method of treatment
GB0205894D0 (en) Method and apparatus for the administration of benefits
SI1539115T1 (sl) Postopki in dozirne oblike za nadzirano dajanje paliperidona
NO20043238L (no) Nelfinavirtablett med oket dosering og fremgangsmate for fremstilling derav
GB0213198D0 (en) Method of treatment
GB0201324D0 (en) Method of and apparatus for account

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees